美国 · SEC FORM 4
Oruka Therapeutics, Inc.
ORKA · Nasdaq · CIK 0000907654 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
130 同一窗口内观察到的 Form 4 交易行
93 sales · 37 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-02-14 · Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P. · $1.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Agarwal ArjunSenior Vice President, Finance
▼○▼○▼○▼▼▼○▼
Goncalves JoanaChief Medical Officer
▼○▼○▼○▼○▼
Quinlan Paul TGeneral Counsel
▼○▼▼○▼
Sandler Laura LeeChief Operating Officer
▼○▼○▼▼
Klein Lawrence OttoChief Executive Officer
▼○▼▼○▼
Fairmount Funds Management LLC; Fairmount Healthcare Co-Invest III L.P.; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasDirector,TenPercentOwner
○▼
● 买入▼ 卖出○ 其他
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-02-14 · Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P..
近期 Form 4 活动
0买入
117卖出
55其他 Form 4 交易行
48SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出93 sale line(s) · 仅供背景
其他37 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,778,131
- 上期报告
- 7,623,327
- 日均成交量
- 1,230,336
- 回补天数
- 6.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-02-14 | Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P. | 买入 (P) | Common Stock | 88,794 | USD 11.44 | USD 1,015,803 | SEC 申报 ↗ |
| 2025-02-13 | Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P. | 买入 (P) | Common Stock | 14,950 | USD 11.63 | USD 173,868 | SEC 申报 ↗ |
| 2025-02-12 | Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P. | 买入 (P) | Common Stock | 8,971 | USD 11.86 | USD 106,396 | SEC 申报 ↗ |
| 2025-02-11 | Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P. | 买入 (P) | Common Stock | 9,593 | USD 10.95 | USD 105,043 | SEC 申报 ↗ |
| 2025-02-10 | Koh Bong Y; Shah Nimish P; VHCP Co-Investment Holdings III, LLC; VHCP Management EG, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; Venrock Healthcare Capital Partners III, L.P. | 买入 (P) | Common Stock | 574 | USD 10.90 | USD 6,257 | SEC 申报 ↗ |
| 2024-08-16 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 5,818 | USD 2.93 | USD 17,068 | SEC 申报 ↗ |
| 2024-07-25 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 30,227 | USD 3.05 | USD 92,192 | SEC 申报 ↗ |
| 2024-07-24 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 189,856 | USD 3.20 | USD 606,901 | SEC 申报 ↗ |
| 2024-07-11 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 94,537 | USD 3.45 | USD 326,153 | SEC 申报 ↗ |
| 2024-07-10 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 55,463 | USD 3.46 | USD 191,902 | SEC 申报 ↗ |
| 2024-07-09 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 16,917 | USD 3.43 | USD 58,025 | SEC 申报 ↗ |
| 2024-07-08 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 47,492 | USD 3.46 | USD 164,236 | SEC 申报 ↗ |
| 2024-07-05 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 28,326 | USD 3.43 | USD 97,058 | SEC 申报 ↗ |
| 2024-07-03 | JANUS HENDERSON GROUP PLC; Janus Henderson Biotech Innovation Master Fund Ltd | 买入 (P) | Common Stock | 166,042 | USD 3.55 | USD 589,449 | SEC 申报 ↗ |
| 2022-05-25 | Funicular Fund, LP; Ma-Weaver Jacob | 买入 (P) | Common Stock | 64,851 | USD 2.32 | USD 150,454 | SEC 申报 ↗ |
Form 4 申报证据
172 transaction lines in the latest 365-day window; 233 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Goncalves Joana | 卖出 (S) | Common Stock | 7,000 | USD 74.81 | USD 523,648 | SEC 申报 ↗ |
| 2026-10-15 | Goncalves Joana | 期权行权／转换 (M) | Common Stock | 7,000 | USD 7.32 | USD 51,240 | SEC 申报 ↗ |
| 2026-10-12 | Agarwal Arjun | 卖出 (S) | Common Stock | 9,999 | USD 80.60 | USD 805,889 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Goncalves Joana | 卖出 (S) | Common Stock | 7,000 | USD 74.81 | USD 523,648 | SEC 申报 ↗ |
| 2026-10-15 | Goncalves Joana | 期权行权／转换 (M) | Common Stock | 7,000 | USD 7.32 | USD 51,240 | SEC 申报 ↗ |
| 2026-10-12 | Agarwal Arjun | 卖出 (S) | Common Stock | 9,999 | USD 80.60 | USD 805,889 | SEC 申报 ↗ |
| 2026-10-12 | Agarwal Arjun | 期权行权／转换 (M) | Common Stock | 9,999 | USD 15.69 | USD 156,903 | SEC 申报 ↗ |
| 2026-10-01 | Klein Lawrence Otto | 卖出 (S) | Common Stock | 25,000 | USD 83.62 | USD 2,090,593 | SEC 申报 ↗ |
| 2026-10-01 | Klein Lawrence Otto | 期权行权／转换 (M) | Common Stock | 25,000 | USD 7.80 | USD 195,000 | SEC 申报 ↗ |
| 2026-09-21 | Quinlan Paul T | 卖出 (S) | Common Stock | 10,000 | USD 93.64 | USD 936,425 | SEC 申报 ↗ |
| 2026-09-21 | Quinlan Paul T | 期权行权／转换 (M) | Common Stock | 10,000 | USD 7.80 | USD 78,000 | SEC 申报 ↗ |
| 2026-09-21 | Agarwal Arjun | 卖出 (S) | Common Stock | 533 | USD 95.75 | USD 51,035 | SEC 申报 ↗ |
| 2026-09-15 | Sandler Laura Lee | 卖出 (S) | Common Stock | 906 | USD 95.71 | USD 86,713 | SEC 申报 ↗ |
| 2026-09-15 | Quinlan Paul T | 卖出 (S) | Common Stock | 1,039 | USD 95.71 | USD 99,443 | SEC 申报 ↗ |
| 2026-09-15 | Klein Lawrence Otto | 卖出 (S) | Common Stock | 2,452 | USD 95.71 | USD 234,681 | SEC 申报 ↗ |
| 2026-09-15 | Goncalves Joana | 卖出 (S) | Common Stock | 7,947 | USD 92.38 | USD 734,161 | SEC 申报 ↗ |
| 2026-09-15 | Goncalves Joana | 期权行权／转换 (M) | Common Stock | 7,000 | USD 7.32 | USD 51,240 | SEC 申报 ↗ |
| 2026-09-15 | Agarwal Arjun | 卖出 (S) | Common Stock | 560 | USD 95.71 | USD 53,598 | SEC 申报 ↗ |
| 2026-09-11 | Agarwal Arjun | 卖出 (S) | Common Stock | 9,459 | USD 92.23 | USD 872,405 | SEC 申报 ↗ |
| 2026-09-11 | Agarwal Arjun | 期权行权／转换 (M) | Common Stock | 9,459 | USD 15.88 | USD 150,175 | SEC 申报 ↗ |
| 2026-09-01 | Sandler Laura Lee | 卖出 (S) | Common Stock | 5,000 | USD 91.82 | USD 459,090 | SEC 申报 ↗ |
| 2026-09-01 | Sandler Laura Lee | 期权行权／转换 (M) | Common Stock | 5,000 | USD 7.80 | USD 39,000 | SEC 申报 ↗ |
| 2026-09-01 | Klein Lawrence Otto | 卖出 (S) | Common Stock | 75,000 | USD 91.84 | USD 6,887,762 | SEC 申报 ↗ |
| 2026-09-01 | Klein Lawrence Otto | 期权行权／转换 (M) | Common Stock | 75,000 | USD 7.80 | USD 585,000 | SEC 申报 ↗ |
| 2026-08-24 | Edwards Larry Todd | 奖励／授予 (A) | Common Stock | 100,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Goncalves Joana | 卖出 (S) | Common Stock | 7,000 | USD 111.84 | USD 782,863 | SEC 申报 ↗ |
| 2026-08-17 | Goncalves Joana | 期权行权／转换 (M) | Common Stock | 7,000 | USD 7.32 | USD 51,240 | SEC 申报 ↗ |
| 2026-08-14 | Quinlan Paul T | 卖出 (S) | Common Stock | 52,000 | USD 108.49 | USD 5,641,295 | SEC 申报 ↗ |
| 2026-08-14 | Quinlan Paul T | 期权行权／转换 (M) | Common Stock | 52,000 | USD 11.60 | USD 603,000 | SEC 申报 ↗ |
| 2026-08-13 | Agarwal Arjun | 卖出 (S) | Common Stock | 10,000 | USD 106.66 | USD 1,066,553 | SEC 申报 ↗ |
| 2026-08-13 | Agarwal Arjun | 期权行权／转换 (M) | Common Stock | 10,000 | USD 15.69 | USD 156,916 | SEC 申报 ↗ |
| 2026-07-15 | Goncalves Joana | 卖出 (S) | Common Stock | 7,000 | USD 86.28 | USD 603,959 | SEC 申报 ↗ |
| 2026-07-15 | Goncalves Joana | 期权行权／转换 (M) | Common Stock | 7,000 | USD 7.32 | USD 51,240 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ORKA |
| CIK | 0000907654 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 233 transaction lines from 2020-09-21 to 2026-10-15 54 P purchase lines · 117 S sale lines · 62 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.